# C_2020261EN.01000201.xml

| 10.8.2020 | EN | Official Journal of the European Union | C 261/2 |
| --- | --- | --- | --- |

10.8.2020

EN

Official Journal of the European Union

C 261/2

---

Prior notification of a concentration

(Case M.9877 – Pro Diagnostic Group/FutureLife/DISCARE CZ JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2020/C 261/02)

1.

This notification concerns the following undertakings:

| — | Pro Diagnostic Group, a.s (‘PDG’, Slovakia), controlled by Ribera Salud Infraestructuras, S.L.U. (Spain) and Pro Partners Holding, a.s. (Slovakia); |
| --- | --- |

—

Pro Diagnostic Group, a.s (‘PDG’, Slovakia), controlled by Ribera Salud Infraestructuras, S.L.U. (Spain) and Pro Partners Holding, a.s. (Slovakia);

| — | FutureLife a.s. (‘FutureLife’, Czechia), ultimately controlled by Mr. Zbyněk Průša; |
| --- | --- |

—

FutureLife a.s. (‘FutureLife’, Czechia), ultimately controlled by Mr. Zbyněk Průša;

| — | DISCARE a.s. (‘JV’, Czechia), currently solely controlled by PDG. |
| --- | --- |

—

DISCARE a.s. (‘JV’, Czechia), currently solely controlled by PDG.

PDG and FutureLife acquire within the meaning of Articles 3(1)(b) and 3(4) of the Merger Regulation joint control of the JV.

The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2.

| — | for PDG: it operates 12 diagnostic imaging centres in private health facilities in Slovakia in the Magnetic Resonance Imaging (‘MRI’), X-Ray (‘RTG’), Computed Tomography (‘CT’)/ Positron Emission Tomography (‘PET’) and Ultrasonography (‘USG’) modalities; |
| --- | --- |

—

for PDG: it operates 12 diagnostic imaging centres in private health facilities in Slovakia in the Magnetic Resonance Imaging (‘MRI’), X-Ray (‘RTG’), Computed Tomography (‘CT’)/ Positron Emission Tomography (‘PET’) and Ultrasonography (‘USG’) modalities;

| — | for FutureLife: active in the provision of healthcare services and laboratories. The FutureLife group companies mainly operate healthcare clinics providing services in the field of assisted reproduction in central Europe. Some group companies also operate outpatient and inpatient clinics specialized in medical care in areas such as rheumatology, andrology, venous surgery, gastroenterology, urology, treatment of Crohn’s disease and other inflammatory bowel diseases, and plastic surgery; |
| --- | --- |

—

for FutureLife: active in the provision of healthcare services and laboratories. The FutureLife group companies mainly operate healthcare clinics providing services in the field of assisted reproduction in central Europe. Some group companies also operate outpatient and inpatient clinics specialized in medical care in areas such as rheumatology, andrology, venous surgery, gastroenterology, urology, treatment of Crohn’s disease and other inflammatory bowel diseases, and plastic surgery;

| — | for the JV: it will operate a diagnostic imaging centre in the RTG and MRI modalities in Prague. |
| --- | --- |

—

for the JV: it will operate a diagnostic imaging centre in the RTG and MRI modalities in Prague.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004, (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9877 – Pro Diagnostic Group/FutureLife/DISCARE CZ JV

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

| Directorate-General for Competition |
| --- |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---